Company / Total Assets
ELITE PHARMACEUTICALS INC /NV/ Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$96.4M
FY2025
5-year range
$26.2M / $96.4M
FY2021-FY2025
Trend
+15.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has increased for 6 consecutive years, from $24M in FY2019 to $96M in FY2025.
Based on SEC 10-K filings.
$96M in FY2025 with a 5-year CAGR of +31.0%.
Improved from $41M to $96M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- +40.0%
- 5-Year CAGR
- +31.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- ELITE PHARMACEUTICALS INC /NV/'s total assets has grown for 6 consecutive years.
- 5-year CAGR of +31.0%, indicating consistent growth.
- In FY2025, total assets increased 15.2% year-over-year.
- Lowest total assets in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $96.4M | +15.2% |
| FY2024 | $83.7M | +104.6% |
| FY2023 | $40.9M | +16.4% |
| FY2022 | $35.1M | +34.2% |
| FY2021 | $26.2M | +4.9% |
| FY2020 | $25.0M | +2.3% |
| FY2019 | $24.4M | -21.0% |
| FY2018 | $30.9M | -10.0% |
| FY2017 | $34.3M | +8.3% |
| FY2016 | $31.7M | +22.2% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026